Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference
– Multi-franchise strategy ongoing in depression, neurology and neuropsychiatry – – Commercial infrastructure build completed for ZULRESSO™ (brexanolone) injection ahead of March 19, 2019 target PDUFA date – – Statistically significant results achieved in Phase 3 trial of SAGE-217 in postpartum
View HTML
Toggle Summary Sage Therapeutics Announces SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression
– Statistically significant reduction observed in depressive symptoms compared to placebo in women with postpartum depression (PPD) – – Well-tolerated with rapid onset of statistically significant effect (Day 3) through two weeks and maintained for four weeks after treatment – CAMBRIDGE, Mass.
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2019-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 27, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the J.P.
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 5, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 3, 2018 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics to Present at Piper Jaffray 30th Annual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 21, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Piper Jaffray 30 th Annual
View HTML
Toggle Summary Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO™ (brexanolone) Injection
PDUFA goal date extended to March 19, 2019 to finalize REMS No additional clinical data or information requested by the FDA CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2018-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat
View HTML
Toggle Summary Sage Therapeutics to Present at Stifel 2018 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Stifel 2018 Healthcare
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
FDA Advisory Committee Meeting outcome supports approval of ZULRESSO™ (brexanolone) injection as the first medicine specifically indicated for the treatment of postpartum depression (PPD) Continuing to execute commercial strategy for ZULRESSO in PPD ahead of PDUFA target date of December 19, 2018
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2018-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018 , the Compensation Committee of Sage’s
View HTML